• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or keep ADHD medication during breastfeeding and pregnancy is a challenge for women suffering from the condition. There isn't much information on how long-term exposure to these drugs could affect the fetus.

A study recently published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological disorders such as hearing loss or vision, febrile seizures, or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Women who are pregnant and take ADHD medication should evaluate the benefits of using it against the possible risks for the foetus. Physicians do not have the necessary data to give clear guidelines however they can provide information regarding the risks and benefits to assist pregnant women in making informed choices.

A study published in Molecular Psychiatry found that women who took ADHD medications during their early pregnancy did not have a significantly increased risk of fetal cardiac malformations or major structural birth defects. Researchers conducted a large population-based study of case control to assess the frequency of major structural defects in infants born to mothers who were taking stimulants during pregnancy. Pediatric cardiologists and clinical geneticists reviewed the cases to ensure correct classification of the cases and to reduce the chance of bias.

The study of the researchers was not without its limitations. Researchers were unable, in the first place, to separate the effects triggered by the medication from the disorder. This makes it difficult for researchers to determine if the small differences observed between the groups that were exposed to the use of medication or affected by co-morbidities. In addition, the researchers did not examine the long-term outcomes of offspring.

The study did find that babies whose mothers had taken ADHD medication during pregnancy were at a higher risk of being admitted to the neonatal intensive care unit (NICU) than those who were born without any medication or taken off their medication prior to or during pregnancy. This increase was caused by central nervous system disorders. The increased risk of admission was not affected by the stimulant medication used during pregnancy.

Women who took stimulant ADHD medications during pregnancy also had a higher risk of having caesarean sections or one whose baby scored low on the Apgar scale (less than 7). These increases appear to be unrelated to the type of medication used during pregnancy.

Researchers suggest that the minor risks associated with the use ADHD medications in early pregnancies could be offset by the greater benefits to both baby and mother of continued treatment for the woman’s disorder. Physicians should discuss the issue with their patients and, when possible, assist them in developing strategies to improve their coping with adhd without medication abilities that may minimize the effects of her disorder on her daily functioning and relationships.

Medication Interactions

As more women than ever are diagnosed with ADHD and treated with medication, the question of whether to keep or stop treatment during pregnancy is a question that doctors are having to have to face. Most of the time, these decisions are made without solid and reliable evidence in either case, which means that doctors must weigh what medication is given for adhd they know, the experiences of other doctors, and what the research suggests about the subject, along with their own best judgment for each patient.

The issue of risk for infants can be extremely difficult. The research that has been conducted on this topic is based on observations rather than controlled studies, and many of the findings are contradictory. Most studies focus on live-births, which could underestimate the teratogenic impact that can lead to abortions or terminations of pregnancy. The study presented in the journal club addresses these shortcomings by analyzing both the data from deceased and live births.

Conclusion A few studies have shown a positive correlation between ADHD medications and certain birth defects, other studies have not established a link. Most studies have shown that there is a neutral, or slightly negative, impact. In the end, a careful risk/benefit assessment must be conducted in every case.

It can be difficult, if not impossible, for women suffering from ADHD to stop taking their medication. In a recent piece published in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can cause depression and feelings of being isolated. A decrease in medication could also impact the ability to safely drive and to perform work-related tasks which are essential aspects of everyday life for those with ADHD.

She suggests women who are unsure about whether to continue or stop medication in light of their pregnancy consider informing family members, friends and colleagues on the condition, its effects on daily life, and the advantages of continuing the current treatment plan. It will also help a woman feel supported in her decision. It is important to note that some medications can pass through the placenta, so if the patient decides to discontinue her ADHD medication during pregnancy and breastfeeding, she should be aware of the possibility that traces of the drug could be passed on to the baby.

Birth Defects Risk

As the use of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) grows there are concerns about what impact the medications could have on fetuses. A recent study published in the journal Molecular Psychiatry adds to the existing information on this topic. Using two massive data sets researchers were able to examine more than 4.3 million pregnancies and see whether stimulant medication use increased the risk of birth defects. Researchers discovered that, while the overall risk is low, first-trimester ADHD exposure to medication was associated with slightly higher risk of specific heart defects like ventriculoseptal defects.

The authors of the study found no link between early medication use and congenital abnormalities such as facial clefting or club foot. The results are in agreement with previous studies that showed a small, but significant increase in cardiac malformations for women who started taking adhd medication pregnancy (www.Metooo.com) medication prior to the time of pregnancy. The risk grew in the latter half of pregnancy, when a lot of women decide to stop taking their ADHD medications.

Women who took ADHD medication during the first trimester were more likely require a caesarean birth and also have a low Apgar after birth and have a baby that needed help breathing after birth. The researchers of the study could not remove bias in selection since they restricted the study to women with no other medical conditions that could have contributed to the findings.

Researchers hope that their study will help doctors when they encounter pregnant women. They recommend that, while the discussion of the risks and benefits is crucial however, the decision to stop or maintain treatment should be based on each woman's requirements and the severity of her ADHD symptoms.

The authors also caution that, while stopping the medication is an option, it isn't an option to consider due to the high rate of depression and other mental health problems among women who are pregnant or recently post-partum. Further, research shows that women who stop taking their medications will have a tough time adjusting to a life without them once the baby is born.

Nursing

The responsibilities that come with being a new mother can be overwhelming. Women with ADHD who have to deal with their symptoms while attending physician appointments as well as getting adhd medication uk ready for the arrival of a child and getting used to new routines at home can experience severe challenges. As such, many women choose to continue taking their adhd medication list medication throughout the pregnancy.

The majority of stimulant medications are absorbed through breast milk in very small amounts, therefore the risk to the nursing infant is very low. The rate of exposure to medication will differ based on dosage and frequency of administration as well as the time of the day. Additionally, different medications enter the baby’s system through the gastrointestinal tract or breast milk. The impact on the health of a newborn is not completely understood.

Some physicians may discontinue stimulant medication during a woman’s pregnancy due to the absence of research. This is a difficult choice for the patient, who must balance the benefits of keeping her medication against the possible dangers to the foetus. As long as more information is available, doctors can inquire about pregnant patients if they have a background of ADHD or if they plan to take medication in the perinatal stage.

Numerous studies have demonstrated that women can continue to take their ADHD medication safely while breastfeeding and during pregnancy. In response, a growing number of patients are choosing to do this. They have found, in consultation with their doctors, that the benefits of continuing their current medication far outweigh any possible risks.

Women who suffer from ADHD who are planning to breastfeed should seek the advice of a specialist psychiatrist before becoming pregnant. They should review their medications with their prescriber and discuss the pros and cons of continued treatment, including non medication treatment for adhd-pharmacological management strategies. Psychoeducation is also necessary to help pregnant women with ADHD recognize the signs and underlying disorder. They should also be informed about treatment options and strengthen strategies for coping. This should involve a multidisciplinary approach, which includes the GP, obstetricians and psychiatry. Pregnancy counseling should include discussion of a treatment plan for the mother and child, as well as monitoring for signs of deterioration and, if needed adjustments to the medication regimen.